Reshma Kewalramani - 27 Feb 2026 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
CEO & President, Director
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
27 Feb 2026
Net transactions value
-$19,738,855
Form type
4
Filing time
03 Mar 2026, 16:34:23 UTC
Previous filing
26 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kewalramani Reshma CEO & President, Director C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON /s/ Christiana Stevenson, Attorney-in-Fact 03 Mar 2026 0001735944

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale $191,900 -400 -0.29% $479.75 137,878 27 Feb 2026 Direct F1, F2, F3
transaction VRTX Common Stock Sale $57,780 -120 -0.09% $481.50 137,758 27 Feb 2026 Direct F1, F2, F4
transaction VRTX Common Stock Sale $115,882 -240 -0.17% $482.84 137,518 27 Feb 2026 Direct F1, F2, F5
transaction VRTX Common Stock Sale $1,222,696 -2,510 -1.8% $487.13 135,008 27 Feb 2026 Direct F1, F2, F6
transaction VRTX Common Stock Sale $1,600,549 -3,278 -2.4% $488.27 131,730 27 Feb 2026 Direct F1, F2, F7
transaction VRTX Common Stock Sale $225,087 -460 -0.35% $489.32 131,270 27 Feb 2026 Direct F1, F2, F8
transaction VRTX Common Stock Sale $1,336,722 -2,725 -2.1% $490.54 128,545 27 Feb 2026 Direct F1, F2, F9
transaction VRTX Common Stock Sale $466,244 -949 -0.74% $491.30 127,596 27 Feb 2026 Direct F1, F2, F10
transaction VRTX Common Stock Sale $1,243,091 -2,520 -2% $493.29 125,076 27 Feb 2026 Direct F1, F2, F11
transaction VRTX Common Stock Sale $1,729,166 -3,498 -2.8% $494.33 121,578 27 Feb 2026 Direct F1, F2, F12
transaction VRTX Common Stock Sale $7,718,020 -15,580 -13% $495.38 105,998 27 Feb 2026 Direct F1, F2, F13
transaction VRTX Common Stock Sale $2,974,479 -5,995 -5.7% $496.16 100,003 27 Feb 2026 Direct F1, F2, F14
transaction VRTX Common Stock Sale $857,239 -1,725 -1.7% $496.95 98,278 27 Feb 2026 Direct F1, F2, F15
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025.
F2 Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $479.75 (range $479.75 to $479.76).
F4 Open market sales reported on this line occurred at a weighted average price of $481.50 (range $481.50 to $481.51).
F5 Open market sales reported on this line occurred at a weighted average price of $482.84 (range $482.84 to $482.85).
F6 Open market sales reported on this line occurred at a weighted average price of $487.13 (range $486.64 to $487.55).
F7 Open market sales reported on this line occurred at a weighted average price of $488.27 (range $487.82 to $488.56).
F8 Open market sales reported on this line occurred at a weighted average price of $489.32 (range $489.01 to $489.79).
F9 Open market sales reported on this line occurred at a weighted average price of $490.54 (range $490.10 to $491.01).
F10 Open market sales reported on this line occurred at a weighted average price of $491.30 (range $491.13 to $491.85).
F11 Open market sales reported on this line occurred at a weighted average price of $493.29 (range $492.78 to $493.77).
F12 Open market sales reported on this line occurred at a weighted average price of $494.33 (range $493.78 to $494.75).
F13 Open market sales reported on this line occurred at a weighted average price of $495.38 (range $494.79 to $495.78).
F14 Open market sales reported on this line occurred at a weighted average price of $496.16 (range $495.79 to $496.74).
F15 Open market sales reported on this line occurred at a weighted average price of $496.95 (range $496.79 to $497.17).